Ohr Pharma: Annual Report 2015 (Ohr Pharmaceutical) - Jan 1, 2016 - Anticipated additional data presentation from P2 IMPACT study (NCT01678963) for wet AMD at a scientific conference in 2016; Anticipated initiation of P3 trial for wet AMD in Q1 2016; Anticipated data from P2 OHR-1501 study (NCT02511613) of squalamine lactate in combination with Lucentis for neovascular AMD in 2016
Anticipated new P3 trial • Anticipated P2 data • Ophthalmology
|